Scientists Discover Early Gene Change in Pancreatic Cancer

Much of pancreatic cancer’s evasive and deadly nature may come down to low levels of one gene.

Pancreatic cancer kills most patients within months of diagnosis, largely because symptoms don’t appear until the disease has already spread. Now, scientists at Tokyo University of Science have identified a gene whose activity drops dramatically even among the earliest stage pancreatic tumors, offering new clues to why some patients face worse outcomes than others.

The gene, called CTDNEP1, shows significantly reduced activity in stage I pancreatic tumors compared to healthy tissue. Researchers analyzing data from 184 patients found that patients with low CTDNEP1 levels at stage II faced significantly shorter survival times than those with higher levels of the gene.

“CTDNEP1 expression was found to be significantly lower in PDAC tissues compared to normal tissues, especially in early-stage tumors,” the research team reported in Cancer Genomics & Proteomics. This matters because pancreatic ductal adenocarcinoma, or PDAC, is the most common form of pancreatic cancer. It typically evades detection until late stages when five-year survival rates hover below 12 percent.

Gene Activity Drops Alongside Cancer Driver Mutations

The researchers discovered that CTDNEP1 levels drop alongside mutations in pancreatic cancer’s main genetic drivers: KRAS, CDKN2A, TP53, and SMAD4. These are genes that, when mutated, help cancer cells grow and spread. Tumors harboring KRAS mutations (which occur early in pancreatic cancer development) showed substantially lower CTDNEP1 activity than tumors with normal KRAS. The same pattern emerged for TP53 mutations and deletions of tumor suppressor genes CDKN2A and SMAD4.

This early timing distinguishes CTDNEP1 from other biomarkers. While stage I patients with high versus low CTDNEP1 showed no survival differences, stage II patients told a different story. Those with low CTDNEP1 activity had significantly shorter overall survival and disease-specific survival compared to patients with higher levels. Stage II represents a moment when doctors must decide between standard chemotherapy and more aggressive combination treatments.

CTDNEP1 produces an enzyme called a phosphatase. Previous research linked this gene to tumor suppression in medulloblastoma, a type of brain cancer affecting children. Mouse studies showed that losing CTDNEP1 function enhances certain signaling pathways that, when overactive, drive cancer progression. The Tokyo team’s work extends these findings to adult pancreatic cancer, suggesting CTDNEP1 may act as a tumor suppressor across multiple cancer types.

Low Gene Activity Associated With Worse Outcomes

Survival analysis revealed how CTDNEP1 levels relate to patient outcomes across multiple measures. Patients with low CTDNEP1 activity showed worse overall survival, disease-specific survival, disease-free survival, and progression-free survival. These relationships held even after accounting for other clinical factors.

The researchers also uncovered how CTDNEP1 activity relates to the tumor’s biological behavior. Tumors with low CTDNEP1 showed increased activity in pathways related to cellular self-digestion, protein breakdown, and immune responses. High CTDNEP1 tumors displayed enhanced mitochondrial function and metabolic activity. Mitochondria are the cell’s power plants, so this suggests these cancers maintain more normal energy production.

A notable finding emerged when scientists examined immune cell infiltration patterns. CTDNEP1 activity correlated positively with CD4+ T cells, macrophages, neutrophils, and dendritic cells. These are all types of immune cells that patrol the body looking for threats. The correlation suggests the gene may influence whether immune cells can effectively penetrate tumors, a factor increasingly recognized as important for disease progression and response to immunotherapy.

Gene pathway analysis provided additional insights. Tumors with low CTDNEP1 showed increased activity in pathways related to fighting viral infections, recycling cellular components, and immune system checkpoints called PD-L1/PD-1. The connection to PD-L1/PD-1 pathways is notable because checkpoint inhibitors targeting these proteins have revolutionized treatment for other cancers, though they’ve shown limited success in pancreatic disease. Whether CTDNEP1 status relates to immunotherapy response remains an open question for future research.

Stage II Patients Show Starkest Survival Differences

The study examined 177 pancreatic cancer patients with complete survival and gene activity data from The Cancer Genome Atlas. This is a database that collects genetic information from cancer patients. Researchers divided patients into high and low CTDNEP1 groups based on median levels, then tracked outcomes over time.

For stage-specific analysis, the research team found 21 stage I patients with adequate data for survival tracking. While this group showed reduced CTDNEP1 compared to normal tissue, no survival differences emerged between high and low groups. The pattern changed in 146 stage II patients, where low CTDNEP1 strongly correlated with poor outcomes.

Insufficient patient numbers prevented survival analysis for stages III and IV. The research analyzed existing patient data collected in the past from a single database. Though this database (The Cancer Genome Atlas) is the most comprehensive cancer genetics resource available to researchers, the findings still need confirmation in other patient groups.

Future Research Directions and Clinical Possibilities

The early reduction of CTDNEP1 activity offers a molecular signal visible in early-stage tumors. Current screening methods like CA 19-9 blood tests lack sufficient sensitivity and specificity for population-wide screening. Meanwhile, imaging techniques typically detect tumors only after they’ve grown large enough to cause problems.

Authors emphasize that CTDNEP1 requires validation in independent patient cohorts before any clinical application. If validated, CTDNEP1 activity could theoretically be measured through biopsy of suspicious pancreatic lesions, or in high-risk individuals who undergo surveillance due to chronic pancreatitis or inherited cancer syndromes. No such testing strategy currently exists.

The gene’s association with survival in stage II disease could eventually help stratify patients for treatment intensity, though this remains speculative. Oncologists currently lack reliable biomarkers to guide stage II treatment decisions. CTDNEP1 levels might one day help identify which patients need aggressive multi-drug regimens versus those who might fare well with less toxic standard protocols. Of course, this would require prospective clinical trials demonstrating that CTDNEP1-based treatment decisions improve outcomes.

Beyond biomarker potential, CTDNEP1 might eventually become a therapeutic target. If researchers can identify compounds that restore CTDNEP1 function or compensate for its loss, they could potentially slow tumor growth. Alternatively, understanding the downstream effects of CTDNEP1 deficiency could reveal other druggable targets in the pathways it normally regulates. These remain research questions rather than near-term treatment strategies.

The findings add to growing recognition that pancreatic cancer’s aggressive behavior stems partly from its ability to evade immune surveillance while creating a nutrient-rich environment through altered metabolism. CTDNEP1 appears to sit at the intersection of these processes, with correlations to both metabolic activity and immune cell recruitment. Researchers noted that tumors with high CTDNEP1 were enriched in pathways related to oxidative phosphorylation, which is the primary method cells use to generate energy in their mitochondria. This suggests that when CTDNEP1 functions normally, pancreatic cells maintain more efficient metabolism compared to tumors where CTDNEP1 activity has declined.

Laboratory studies should investigate the molecular mechanisms through which CTDNEP1 loss promotes tumor growth and alters immune cell behavior. Previous medulloblastoma research provides a roadmap. Scientists studying that pediatric brain tumor found that CTDNEP1 deficiency triggers MYC gene amplification and genomic instability, considered hallmarks of aggressive cancer. If similar mechanisms operate in pancreatic tumors, therapeutic strategies developed for medulloblastoma might translate to pancreatic cancer treatment.

CTDNEP1 joins a growing list of molecular markers under investigation for pancreatic cancer. Whether it will transition from research finding to clinical tool depends on future validation studies, development of reliable testing methods, and validation that measuring CTDNEP1 actually improves patient outcomes compared to current practice.

For now, scientists can at least say with certainty that its early appearance in stage I tumors and association with survival in stage II disease make it a candidate worth further investigation.

---